CorrespondenceMetastatic basal cell carcinoma with neuroendocrine differentiation: complete response to cemiplimab.

Authors :: Marti-Marti I
Puig S
Albero-González R
Masferrer E
Iglesias P
Pérez-Anker J
Serra-García L
Tarroch X
Curcó N
Toll A
Source :: Clinical and experimental dermatology [Clin Exp Dermatol] 2024 Aug 22; Vol. 49 (9), pp. 1060-1062.
Publication Year :: 2024
Abstract: Competing Interests: Conflicts of interest S.P. is advisor and speaker for Sanofi and Regeneron. S.P. and A.T. have participated in the clinical trial R2810-ONC-1540 (Regeneron Pharmaceutics Incs and Sanofi-Aventis, LLC). The other authors declare no conflicts of interest.

Subjects :: Humans
Antineoplastic Agents, Immunological therapeutic use
Carcinoma, Neuroendocrine drug therapy
Carcinoma, Neuroendocrine pathology
Male
Aged
Female
Antibodies, Monoclonal, Humanized therapeutic use
Skin Neoplasms drug therapy
Skin Neoplasms pathology
Carcinoma, Basal Cell drug therapy
Carcinoma, Basal Cell pathology

Full Text Access

Tools